Back
Article
Morgan Stanley Downgrades Aardvark Therapeutics to Equal-Weight, Lowers Price Target to $7
Benzinga Newsdesk  |  Mar 02, 2026 11:21  |  Source: www.benzinga.com
Morgan Stanley analyst Michael Ulz downgrades Aardvark Therapeutics (NASDAQ:AARD) from Overweight to Equal-Weight and lowers the price target from $29 to $7.
Comments
  • No comments yet. Be the first to comment!

Login to comment